ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Vyndaqel 20 mg, Weichkapseln - 30
67083001 Pfizer AG
Vyndaqel 20 mg, Weichkapseln05.03.2020
  05.03.2020
Tafamidis (N07XX08) 
WHO-DDD 
30
01.99. 
B  
No 
IPCI
PR  
k.A.PR
  
7680670830010Synthetika
  
Composition
tafamidisum megluminum 20 mg corresp. tafamidisum 12.2 mg, macrogolum 400, polysorbatum 80, sorbitani oleas, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (flavum), E 171, Drucktinte: macrogolum 400, propylenglycolum, polyvinylis acetas phtalas, E 120, E 133, pro capsula.
Packungsbestandteile
Soft capsules
 
Active AgentDose
Tafamidisum Megluminum20 mg correspond Tafamidisum 12.2 mg
 
Inactive agentsDoseadditional_information
(Flavum)  
E 120 color.
E 133 color.
E 171 color.
E 172 color.
Gelatina Kapselhülle
Glycerol  
Macrogol400 Drucktinte
Polysorbatum 80  
Polyvinylis Acetas Phtalas  
Pro Capsula  
Propylenglycol  
Sorbitani Oleas  
Sorbitolum Liquidum Partim Deshydricum  
Source
Data was imported : 07.08.2024 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home